Search

Your search keyword '"de Bruin-Weller, M. S."' showing total 221 results
Start Over Author "de Bruin-Weller, M. S."
221 results on '"de Bruin-Weller, M. S."'

1. Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study

Author

ter Haar, E. L. M., Thomas, S. E., van den Reek, J. M. P. A., Otero, M. E., Njoo, M. D., Ossenkoppele, P. M., Kop, E. N., Dodemont, S. R. P., Körver, J. E. M., Kuijpers, A. L. A., Lindhout, R. J., Tupker, R. A., Mommers, J. M., Berends, M. A. M., Koetsier, M. I. A., de Bruin-Weller, M. S., Visch, M. B., Arnold, W. P., van Lümig, P. P. M., Kleinpenning, M. M., Lubeek, S. F. K., and de Jong, E. M. G. J.

Published
2022
Full Text
View/download PDF

2. Higher Levels of Response on Clinical Atopic Dermatitis Severity Measures Are Associated with Meaningful Improvements in Patient‐Reported Symptom and Quality of Life Measures: Integrated Analysis of Three Upadacitinib Phase 3 Trials

Author

Reich, K., primary, de Bruin‐Weller, M. S., additional, Deleuran, M., additional, Calimlim, B. M., additional, Chen, N., additional, Hu, X., additional, Tenorio, A. R., additional, and Silverberg, J. I., additional

Published
2023
Full Text
View/download PDF

9. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis

Author

MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CTI Van Wijk, CTI UDAIR, CTI Borghans, CDL Patiëntenzorg MI, CTI Research, Cancer, Child Health, Bakker, D S, van der Wal, M M, Heeb, L E M, Giovannone, B, Asamoah, M, Delemarre, E M, Drylewicz, J, Nierkens, S, Boyman, O, de Bruin-Weller, M S, Thijs, J L, Wijk, F van, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CTI Van Wijk, CTI UDAIR, CTI Borghans, CDL Patiëntenzorg MI, CTI Research, Cancer, Child Health, Bakker, D S, van der Wal, M M, Heeb, L E M, Giovannone, B, Asamoah, M, Delemarre, E M, Drylewicz, J, Nierkens, S, Boyman, O, de Bruin-Weller, M S, Thijs, J L, and Wijk, F van

Published
2021

10. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics

Author

MS Dermatologie/Allergologie, Infection & Immunity, Thyssen, J P, Vestergaard, C, Barbarot, S, de Bruin-Weller, M S, Bieber, T, Taieb, A, Seneschal, J, Cork, M J, Paul, C, Flohr, C, Weidinger, S, Trzeciak, M, Werfel, T, Heratizadeh, A, Darsow, U, Simon, D, Torrelo, A, Chernyshov, P V, Stalder, J-F, Gelmetti, C, Szalai, Z, Svensson, Å, von Kobyletzki, L B, De Raeve, L, Fölster-Holst, R, Christen-Zaech, S, Hijnen, D J, Gieler, U, Gutermuth, J, Bangert, C, Spuls, P I, Kunz, B, Ring, J, Wollenberg, A, Deleuran, M, MS Dermatologie/Allergologie, Infection & Immunity, Thyssen, J P, Vestergaard, C, Barbarot, S, de Bruin-Weller, M S, Bieber, T, Taieb, A, Seneschal, J, Cork, M J, Paul, C, Flohr, C, Weidinger, S, Trzeciak, M, Werfel, T, Heratizadeh, A, Darsow, U, Simon, D, Torrelo, A, Chernyshov, P V, Stalder, J-F, Gelmetti, C, Szalai, Z, Svensson, Å, von Kobyletzki, L B, De Raeve, L, Fölster-Holst, R, Christen-Zaech, S, Hijnen, D J, Gieler, U, Gutermuth, J, Bangert, C, Spuls, P I, Kunz, B, Ring, J, Wollenberg, A, and Deleuran, M

Published
2021

18. Dupilumab : Eerste resultaten vanuit het BioDay-register

Author

Ariëns, Lieneke F.M., van der Schaft, J., Bakker, D. S., Balak, D. M.W., Giovannone, B., Romeijn, M., Kouwenhoven, T., Kamsteeg, M., Drylewicz, J., van Wijk, F., Nierkens, Stefan, Thijs, J. L., Schuttelaar, M. L., and de Bruin-Weller, M. S.

Subjects
Infectious Diseases, Biologic, Dupilumab, Daily practice, Critical Care and Intensive Care Medicine, Atopic dermatitis
Abstract

The effectiveness and safety of dupilumab for the treatment of moderate to severe atopic dermatitis (AD) has been demonstrated in phase III clinical trials. At this moment, daily practice data on dupilumab treatment with respect to clinical effectiveness and safety are scarce. The objective of this study was to study the clinical effectiveness of 16 weeks treatment with dupilumab in adult patients with moderate to severe AD in daily practice. Data were extracted from the BioDay registry, a prospective multicenter registry. Sixteen-weeks clinical effectiveness of dupilumab was expressed as number of patients achieving EASI-50, EASI-75 as well as patient reported outcome measures (POEM, DLQI, NRS-pruritus). A clinically relevant response was defined based on thresholds in one or more outcomes of the 3 major AD domains (EASI, NRS-pruritus, DLQI). In total, 138 patients treated with dupilumab in daily practice were included. This cohort included patients with very difficult- to-treat AD with 84 patients (61%) who failed treatment on ≥2 immunosuppressive drugs. At week 16, the mean percent change in EASI score was 73%. The EASI-50 and EASI-75 was achieved by 114 (86%) and 82 (62%) patients after 16 weeks of treatment. Also patient-reported outcomes including sleep, itch and quality of life significantly improved during dupilumab treatment. A clinically relevant response was achieved by 89% of the patients after 16 weeks of treatment. The most reported side effects were conjunctivitis in 47 (34%) and eosinophilia in 78 (57%) patients. In conclusion, treatment with dupilumab significantly improved signs and symptoms of AD in patients with very difficult-to-treat AD in a daily practice setting with the majority of patients achieving a clinically relevant response after 16 weeks of treatment.

Published
2019

36. Dupilumab: Eerste resultaten vanuit het BioDay-register

Author

MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CTI Borghans, CTI Van Wijk, Child Health, CTI Research, CDL Patiëntenzorg MI, CTI Nierkens, CTI UDAIR, Ariëns, Lieneke F.M., van der Schaft, J., Bakker, D. S., Balak, D. M.W., Giovannone, B., Romeijn, M., Kouwenhoven, T., Kamsteeg, M., Drylewicz, J., van Wijk, F., Nierkens, Stefan, Thijs, J. L., Schuttelaar, M. L., de Bruin-Weller, M. S., MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CTI Borghans, CTI Van Wijk, Child Health, CTI Research, CDL Patiëntenzorg MI, CTI Nierkens, CTI UDAIR, Ariëns, Lieneke F.M., van der Schaft, J., Bakker, D. S., Balak, D. M.W., Giovannone, B., Romeijn, M., Kouwenhoven, T., Kamsteeg, M., Drylewicz, J., van Wijk, F., Nierkens, Stefan, Thijs, J. L., Schuttelaar, M. L., and de Bruin-Weller, M. S.

Published
2019

37. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis

Author

MS Dermatologie/Allergologie, MS Oogheelkunde, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Immuno/reuma onderzoek 4, Onderzoek, Child Health, Infection & Immunity, CTI, Pathologie Pathologen staf, Cancer, Bakker, D S, Ariens, L F M, van Luijk, C, van der Schaft, J, Thijs, J L, Schuttelaar, M L A, van Wijk, F, Knol, E F, Balak, D M W, van Dijk, M R, de Bruin-Weller, M S, MS Dermatologie/Allergologie, MS Oogheelkunde, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Immuno/reuma onderzoek 4, Onderzoek, Child Health, Infection & Immunity, CTI, Pathologie Pathologen staf, Cancer, Bakker, D S, Ariens, L F M, van Luijk, C, van der Schaft, J, Thijs, J L, Schuttelaar, M L A, van Wijk, F, Knol, E F, Balak, D M W, van Dijk, M R, and de Bruin-Weller, M S

Published
2019

38. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion

Author

Thyssen, J. P., de Bruin-Weller, M. S., Paller, A. S., Leshem, Y. A., Vestergaard, C., Deleuran, M., Drucker, A. M., Foelster-Holst, R., Traidl-Hoffmann, C., Eyerich, K., Taieb, A., Su, J. C., Bieber, T., Cork, M. J., Eichenfield, L. F., Guttman-Yassky, E., Wollenberg, A., Thyssen, J. P., de Bruin-Weller, M. S., Paller, A. S., Leshem, Y. A., Vestergaard, C., Deleuran, M., Drucker, A. M., Foelster-Holst, R., Traidl-Hoffmann, C., Eyerich, K., Taieb, A., Su, J. C., Bieber, T., Cork, M. J., Eichenfield, L. F., Guttman-Yassky, E., and Wollenberg, A.

Abstract

Background: Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab. Objective: To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Council (IEC). Methods: Electronic survey and in-person discussion of management strategies. Results: Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupilumab treatment should be continued when possible, with appropriate referral to an ophthalmologist. Limitations: The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupilumab access were not excluded from the survey. Conclusion: The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during treatment with dupilumab.

Published
2019

40. Samenvatting Leidraad Dermatocorticosteroïden

Author

Teligui, Leylah, Arents, B. W. M., Galimont, A. F. S., Geleedst-de Vooght, M. M. M., van Lümig, P. P. M., Rustemeyer, T., de Bruin-Weller, M. S., Middelkamp Hup, M. A., Dermatology, VU University medical center, APH - Quality of Care, CCA - Cancer Treatment and Quality of Life, CCA - Imaging and biomarkers, and APH - Methodology

Published
2018

42. Is there an increased risk of cervical neoplasia in atopic dermatitis patients treated with oral immunosuppressive drugs?

Author

Garritsen, F. M., Verheijen, R. H.M., Gerestein, C. G., van Zuilen, A. D., Oosterhaven, J. A.F., van Dijk, M., Bruijnzeel-Koomen, C. A.F., Schuttelaar, M. L., de Bruin-Weller, M. S., Garritsen, F. M., Verheijen, R. H.M., Gerestein, C. G., van Zuilen, A. D., Oosterhaven, J. A.F., van Dijk, M., Bruijnzeel-Koomen, C. A.F., Schuttelaar, M. L., and de Bruin-Weller, M. S.

Published
2018

43. Is there an increased risk of cervical neoplasia in atopic dermatitis patients treated with oral immunosuppressive drugs?

Author

Unit Opleiding Dermatologie, MS Gynaecologische Oncologie, MS Nefrologie, Circulatory Health, Project Ondersteuning, MS Dermatologie/Allergologie, Infection & Immunity, Garritsen, F. M., Verheijen, R. H.M., Gerestein, C. G., van Zuilen, A. D., Oosterhaven, J. A.F., van Dijk, M., Bruijnzeel-Koomen, C. A.F., Schuttelaar, M. L., de Bruin-Weller, M. S., Unit Opleiding Dermatologie, MS Gynaecologische Oncologie, MS Nefrologie, Circulatory Health, Project Ondersteuning, MS Dermatologie/Allergologie, Infection & Immunity, Garritsen, F. M., Verheijen, R. H.M., Gerestein, C. G., van Zuilen, A. D., Oosterhaven, J. A.F., van Dijk, M., Bruijnzeel-Koomen, C. A.F., Schuttelaar, M. L., and de Bruin-Weller, M. S.

Published
2018

44. Use of systemic corticosteroids for atopic dermatitis:International Eczema Council consensus statement

Author

Drucker, A M, Eyerich, K, de Bruin-Weller, M S, Thyssen, J P, Spuls, P I, Irvine, A D, Girolomoni, G, Dhar, S, Flohr, C, Murrell, D F, Paller, A S, Guttman-Yassky, E, Drucker, A M, Eyerich, K, de Bruin-Weller, M S, Thyssen, J P, Spuls, P I, Irvine, A D, Girolomoni, G, Dhar, S, Flohr, C, Murrell, D F, Paller, A S, and Guttman-Yassky, E

Abstract

BACKGROUND: Guidelines discourage the use of systemic corticosteroids for atopic dermatitis (AD), but their use remains widespread.OBJECTIVES: To reach consensus among an international group of AD experts on the use of systemic corticosteroids for AD.METHODS: A survey consisting of statements accompanied by visual analogue scales ranging from 'strongly disagree' to 'neutral' to 'strongly agree' was distributed to the International Eczema Council (IEC). Consensus was reached in agreement on a statement if < 30% of respondents marked to the left of 'neutral' towards 'strongly disagree'.RESULTS: Sixty of 77 (78%) IEC members participated. Consensus was reached on 12 statements, including that systemic corticosteroids should generally be avoided but can be used rarely for severe AD under certain circumstances, including a lack of other treatment options, as a bridge to other systemic therapies or phototherapy, during acute flares in need of immediate relief, in anticipation of a major life event or in the most severe cases. If used, treatment should be limited to the short term. Most respondents agreed that systemic corticosteroids should never be used in children, but consensus was not reached on that statement. The conclusions of our expert group are limited by a dearth of high-quality published evidence. If more stringent consensus criteria were applied (e.g. requiring < 20% of respondents marking towards 'strongly disagree'), consensus would have been reached on fewer statements.CONCLUSIONS: Based on expert opinion from the IEC, routine use of systemic corticosteroids for AD is generally discouraged and should be reserved for special circumstances.

Published
2018

45. Biologicals bij constitutioneel eczeem

Author

De Bruin-Weller, M. S.

Subjects
Infectious Diseases, Critical Care and Intensive Care Medicine
Abstract

In the past decennia systemic immunosuppressive treatment options in moderate to severe atopic dermatitis (AD) were limited. Oral immunosuppressive drugs, such as cyclosporine A (CsA), azathioprine, methotrexate and mycophenolic acid are used regularly, however a high a percentage of patients discontinue treatment due to inefficacy and/or side effects. In 2014 the first results of a phase 1 trial with dupilumab, a fully-human monoclonal antibody directed against the interleukin-4 receptor, in the treatment moderate to severe AD, were published. Dupilumab resulted in a rapid and a strong reduction of eczema an pruritus. An extensive phase 2 /3 dupilumab study was conducted, involving more than 2500 patients with moderate to severe AD. In 2 randomized, double-blind, placebo-controlled phase 3 trials including 1379 patients with moderate-to-severe AD and inadequate response to topical medications, dupilumab monotherapy resulted in a 50[%] reduction of EASI score in 61-69[%] of the patients (placebo groups 22-25[%]); EASI 75 was reached in 44-52[%] in the dupilumab groups compared to 12-15[%] in the placebo groups. The results of long-term treatment with dupilumab (52 weeks, concomitant treatment with topical steroids) show a consistent significant effect on all outcome measures. The results of a study including patients with a history of failure of CsA treatment (side effects or inefficacy) or with contra-indication to CsA treatment are expected shortly. Recently phase 1 and 2 studies with monoclonal antibodies directed against IL-13 and IL-31 were performed. The first results of IL-31 treatment are published and show a significant effect on pruritus and sleep disturbances in AD patients.

Published
2017

50. Atopic dermatitis characteristics and medication-use patterns in school-age children with AD and asthma symptoms

Author

Lee, M., Arabkhazaeli, Ali, van Erp, F. C., Raaijmakers, Antonia J A, van der Ent, C. K., Bruijnzeel-Koomen, C. A.F.M., de Bruin-Weller, M. S., Vijverberg, S. J.H., Maitland-van der Zee, Anke H., Lee, M., Arabkhazaeli, Ali, van Erp, F. C., Raaijmakers, Antonia J A, van der Ent, C. K., Bruijnzeel-Koomen, C. A.F.M., de Bruin-Weller, M. S., Vijverberg, S. J.H., and Maitland-van der Zee, Anke H.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results